308 related articles for article (PubMed ID: 29604931)
1. Next-Generation Sequencing for Minimal Residual Disease Surveillance in Acute Lymphoblastic Leukemia: An Update.
Reyes-Barron C; Burack WR; Rothberg PG; Ding Y
Crit Rev Oncog; 2017; 22(5-6):559-567. PubMed ID: 29604931
[TBL] [Abstract][Full Text] [Related]
2. Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
Kotrova M; Trka J; Kneba M; Brüggemann M
Mol Diagn Ther; 2017 Oct; 21(5):481-492. PubMed ID: 28452038
[TBL] [Abstract][Full Text] [Related]
3. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
Gaipa G; Basso G; Biondi A; Campana D
Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
[TBL] [Abstract][Full Text] [Related]
4. Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia.
Mai H; Li Q; Wang G; Wang Y; Liu S; Tang X; Chen F; Zhou G; Liu Y; Li T; Wang L; Wang C; Wen F; Liu S
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3259-3266. PubMed ID: 35918464
[TBL] [Abstract][Full Text] [Related]
5. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.
Nunes V; Cazzaniga G; Biondi A
Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
[TBL] [Abstract][Full Text] [Related]
7. How I investigate minimal residual disease in acute lymphoblastic leukemia.
Correia RP; Bento LC; de Sousa FA; Barroso RS; Campregher PV; Bacal NS
Int J Lab Hematol; 2021 Jun; 43(3):354-363. PubMed ID: 33423385
[TBL] [Abstract][Full Text] [Related]
8. Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It.
Short NJ; Jabbour E
Curr Oncol Rep; 2017 Jan; 19(1):6. PubMed ID: 28205134
[TBL] [Abstract][Full Text] [Related]
9. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study.
Brüggemann M; Kotrová M; Knecht H; Bartram J; Boudjogrha M; Bystry V; Fazio G; Froňková E; Giraud M; Grioni A; Hancock J; Herrmann D; Jiménez C; Krejci A; Moppett J; Reigl T; Salson M; Scheijen B; Schwarz M; Songia S; Svaton M; van Dongen JJM; Villarese P; Wakeman S; Wright G; Cazzaniga G; Davi F; García-Sanz R; Gonzalez D; Groenen PJTA; Hummel M; Macintyre EA; Stamatopoulos K; Pott C; Trka J; Darzentas N; Langerak AW;
Leukemia; 2019 Sep; 33(9):2241-2253. PubMed ID: 31243313
[TBL] [Abstract][Full Text] [Related]
10. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.
Huang YJ; Coustan-Smith E; Kao HW; Liu HC; Chen SH; Hsiao CC; Yang CP; Jaing TH; Yeh TC; Kuo MC; Lai CL; Chang CH; Campana D; Liang DC; Shih LY
J Formos Med Assoc; 2017 Oct; 116(10):774-781. PubMed ID: 28063722
[TBL] [Abstract][Full Text] [Related]
11. Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL.
Cheng S; Inghirami G; Cheng S; Tam W
J Hematol Oncol; 2018 Aug; 11(1):105. PubMed ID: 30134947
[TBL] [Abstract][Full Text] [Related]
12. How do we measure MRD in ALL and how should measurements affect decisions. Re: Treatment and prognosis?
Chen X; Wood BL
Best Pract Res Clin Haematol; 2017 Sep; 30(3):237-248. PubMed ID: 29050697
[TBL] [Abstract][Full Text] [Related]
13. Validation of a PCR-Based Next-Generation Sequencing Approach for the Detection and Quantification of Minimal Residual Disease in Acute Lymphoblastic Leukemia and Multiple Myeloma Using gBlocks as Calibrators.
Van der Straeten J; De Brouwer W; Kabongo E; Dresse MF; Fostier K; Schots R; Van Riet I; Bakkus M
J Mol Diagn; 2021 May; 23(5):599-611. PubMed ID: 33549860
[TBL] [Abstract][Full Text] [Related]
14. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia?
Szczepański T
Leukemia; 2007 Apr; 21(4):622-6. PubMed ID: 17301806
[TBL] [Abstract][Full Text] [Related]
15. Detection of minimal residual disease in acute leukemia.
van der Velden VH; Boeckx N; van Wering ER; van Dongen JJ
J Biol Regul Homeost Agents; 2004; 18(2):146-54. PubMed ID: 15471219
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Measurable Residual Disease in Pediatric B-Lymphoblastic Leukemia Using Multiparametric Flow Cytometry and Next-Generation Sequencing.
Hwang SM; Oh I; Kwon SR; Lee JS; Seong MW
Ann Lab Med; 2024 Jul; 44(4):354-358. PubMed ID: 38237930
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma.
Shirai R; Osumi T; Keino D; Nakabayashi K; Uchiyama T; Sekiguchi M; Hiwatari M; Yoshida M; Yoshida K; Yamada Y; Tomizawa D; Takae S; Kiyokawa N; Matsumoto K; Yoshioka T; Hata K; Hori T; Suzuki N; Kato M
Int J Hematol; 2023 Jun; 117(6):910-918. PubMed ID: 36867356
[TBL] [Abstract][Full Text] [Related]
18. Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia.
Kruse A; Abdel-Azim N; Kim HN; Ruan Y; Phan V; Ogana H; Wang W; Lee R; Gang EJ; Khazal S; Kim YM
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033444
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease studies in acute leukemia.
Campana D
Am J Clin Pathol; 2004 Dec; 122 Suppl():S47-57. PubMed ID: 15690642
[TBL] [Abstract][Full Text] [Related]
20. Association of minimal residual disease with clinical outcomes in Philadelphia chromosome positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era: A systemic literature review and meta-analysis.
Zhang W; Jang E
PLoS One; 2021; 16(8):e0256801. PubMed ID: 34437635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
